Compile Data Set for Download or QSAR

Found 286 hits with Last Name = 'miller' and Initial = 'i'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Plasma kallikrein (Homo sapiens (Human))	BDBM263238 (5-amino-1-(4-pyrazol-1-ylmethyl-benzyl)-1h-pyrazol...) Show SMILES Nc1nn(Cc2ccc(Cn3cccn3)cc2)cc1C(=O)NCc1ccc2c(N)nccc2c1 Show InChI InChI=1S/C25H24N8O/c26-23-21-7-6-19(12-20(21)8-10-28-23)13-29-25(34)22-16-33(31-24(22)27)15-18-4-2-17(3-5-18)14-32-11-1-9-30-32/h1-12,16H,13-15H2,(H2,26,28)(H2,27,31)(H,29,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.330	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263258 (3-amino-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(N)n3)cc2)c1 Show InChI InChI=1S/C26H26N8O/c1-17-11-31-33(13-17)14-18-2-4-19(5-3-18)15-34-16-23(25(28)32-34)26(35)30-12-20-6-7-22-21(10-20)8-9-29-24(22)27/h2-11,13,16H,12,14-15H2,1H3,(H2,27,29)(H2,28,32)(H,30,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.670	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263231 (3-cyano-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C#N)cc2)c1 Show InChI InChI=1S/C27H24N8O/c1-18-12-32-34(14-18)15-19-2-4-20(5-3-19)16-35-17-24(25(11-28)33-35)27(36)31-13-21-6-7-23-22(10-21)8-9-30-26(23)29/h2-10,12,14,17H,13,15-16H2,1H3,(H2,29,30)(H,31,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.740	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263235 (3-(3,5-dimethyl-isoxazol-4-yl)-1-[4-(4-methyl-pyra...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)-c3c(C)noc3C)cc2)c1 |(-10.81,-15.06,;-10.81,-13.52,;-12.06,-12.61,;-11.58,-11.15,;-10.04,-11.15,;-9.14,-9.9,;-7.6,-10.06,;-6.7,-8.82,;-5.17,-8.98,;-4.54,-10.38,;-3.01,-10.55,;-2.1,-9.3,;-2.58,-7.84,;-1.33,-6.93,;-1.33,-5.39,;-2.67,-4.62,;,-4.62,;,-3.08,;1.33,-2.31,;1.33,-.77,;2.67,,;4,-.77,;5.33,,;5.33,1.54,;6.67,-.77,;6.67,-2.31,;5.33,-3.08,;4,-2.31,;2.67,-3.08,;-.09,-7.84,;-.56,-9.3,;1.38,-7.36,;1.85,-5.89,;.95,-4.65,;3.39,-5.89,;3.87,-7.36,;2.62,-8.26,;2.62,-9.8,;-5.45,-11.63,;-6.98,-11.47,;-9.56,-12.61,)| Show InChI InChI=1S/C31H30N8O2/c1-19-13-35-38(15-19)16-22-4-6-23(7-5-22)17-39-18-27(29(36-39)28-20(2)37-41-21(28)3)31(40)34-14-24-8-9-26-25(12-24)10-11-33-30(26)32/h4-13,15,18H,14,16-17H2,1-3H3,(H2,32,33)(H,34,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.890	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263298 (1-(4-pyrazol-1-ylmethyl-benzyl)-3-trifluoromethyl-...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(Cn5cccn5)cc4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C26H22F3N7O/c27-26(28,29)23-22(25(37)32-13-19-6-7-21-20(12-19)8-10-31-24(21)30)16-36(34-23)15-18-4-2-17(3-5-18)14-35-11-1-9-33-35/h1-12,16H,13-15H2,(H2,30,31)(H,32,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.920	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263229 (3-hydroxymethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(CO)n3)cc2)c1 Show InChI InChI=1S/C27H27N7O2/c1-18-11-31-33(13-18)14-19-2-4-20(5-3-19)15-34-16-24(25(17-35)32-34)27(36)30-12-21-6-7-23-22(10-21)8-9-29-26(23)28/h2-11,13,16,35H,12,14-15,17H2,1H3,(H2,28,29)(H,30,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.17	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263259 (3-methoxymethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)...) Show SMILES COCc1nn(Cc2ccc(Cn3cc(C)cn3)cc2)cc1C(=O)NCc1ccc2c(N)nccc2c1 Show InChI InChI=1S/C28H29N7O2/c1-19-12-32-34(14-19)15-20-3-5-21(6-4-20)16-35-17-25(26(33-35)18-37-2)28(36)31-13-22-7-8-24-23(11-22)9-10-30-27(24)29/h3-12,14,17H,13,15-16,18H2,1-2H3,(H2,29,30)(H,31,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.27	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263261 (3-difluoromethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C(F)F)cc2)c1 Show InChI InChI=1S/C27H25F2N7O/c1-17-11-33-35(13-17)14-18-2-4-19(5-3-18)15-36-16-23(24(34-36)25(28)29)27(37)32-12-20-6-7-22-21(10-20)8-9-31-26(22)30/h2-11,13,16,25H,12,14-15H2,1H3,(H2,30,31)(H,32,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.68	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263221 (3-methyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(C)n3)cc2)c1 Show InChI InChI=1S/C27H27N7O/c1-18-12-31-33(14-18)15-20-3-5-21(6-4-20)16-34-17-25(19(2)32-34)27(35)30-13-22-7-8-24-23(11-22)9-10-29-26(24)28/h3-12,14,17H,13,15-16H2,1-2H3,(H2,28,29)(H,30,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.89	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263248 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-pyra...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(cn3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1 Show InChI InChI=1S/C26H25N7O/c1-18-11-30-32(14-18)15-19-2-4-20(5-3-19)16-33-17-23(13-31-33)26(34)29-12-21-6-7-24-22(10-21)8-9-28-25(24)27/h2-11,13-14,17H,12,15-16H2,1H3,(H2,27,28)(H,29,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263224 (3-isopropyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-ben...) Show SMILES CC(C)c1nn(Cc2ccc(Cn3cc(C)cn3)cc2)cc1C(=O)NCc1ccc2c(N)nccc2c1 Show InChI InChI=1S/C29H31N7O/c1-19(2)27-26(29(37)32-14-23-8-9-25-24(12-23)10-11-31-28(25)30)18-36(34-27)17-22-6-4-21(5-7-22)16-35-15-20(3)13-33-35/h4-13,15,18-19H,14,16-17H2,1-3H3,(H2,30,31)(H,32,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.14	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263342 (1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-benzyl]-3-trifl...) Show SMILES FC(F)(F)c1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1n[nH]c2ccc(Cl)cc12 Show InChI InChI=1S/C26H20ClF3N6O2/c27-18-8-9-21-19(11-18)22(33-32-21)12-31-25(38)20-15-36(34-24(20)26(28,29)30)14-17-6-4-16(5-7-17)13-35-10-2-1-3-23(35)37/h1-11,15H,12-14H2,(H,31,38)(H,32,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.14	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263253 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-3-trifl...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C(F)(F)F)cc2)c1 Show InChI InChI=1S/C27H24F3N7O/c1-17-11-34-36(13-17)14-18-2-4-19(5-3-18)15-37-16-23(24(35-37)27(28,29)30)26(38)33-12-20-6-7-22-21(10-20)8-9-32-25(22)31/h2-11,13,16H,12,14-15H2,1H3,(H2,31,32)(H,33,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.16	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263301 (1-(6-pyrazol-1-ylmethyl-pyridin-3-ylmethyl)-3-trif...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(Cn5cccn5)nc4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C25H21F3N8O/c26-25(27,28)22-21(24(37)32-11-16-3-5-20-18(10-16)6-8-30-23(20)29)15-36(34-22)13-17-2-4-19(31-12-17)14-35-9-1-7-33-35/h1-10,12,15H,11,13-14H2,(H2,29,30)(H,32,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.29	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263215 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-imid...) Show SMILES Cc1cnn(Cc2ccc(Cn3cnc(c3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1 Show InChI InChI=1S/C26H25N7O/c1-18-11-31-33(13-18)15-20-4-2-19(3-5-20)14-32-16-24(30-17-32)26(34)29-12-21-6-7-23-22(10-21)8-9-28-25(23)27/h2-11,13,16-17H,12,14-15H2,1H3,(H2,27,28)(H,29,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.40	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263215 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-imid...) Show SMILES Cc1cnn(Cc2ccc(Cn3cnc(c3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1 Show InChI InChI=1S/C26H25N7O/c1-18-11-31-33(13-18)15-20-4-2-19(3-5-20)14-32-16-24(30-17-32)26(34)29-12-21-6-7-23-22(10-21)8-9-28-25(23)27/h2-11,13,16-17H,12,14-15H2,1H3,(H2,27,28)(H,29,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.40	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263223 (3-cyclopropyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-b...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C3CC3)cc2)c1 Show InChI InChI=1S/C29H29N7O/c1-19-13-33-35(15-19)16-20-2-4-21(5-3-20)17-36-18-26(27(34-36)23-7-8-23)29(37)32-14-22-6-9-25-24(12-22)10-11-31-28(25)30/h2-6,9-13,15,18,23H,7-8,14,16-17H2,1H3,(H2,30,31)(H,32,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.58	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263250 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-[1,2...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(nn3)C(=O)NCc3ccc4c(N)nccc4c3)cc2)c1 Show InChI InChI=1S/C25H24N8O/c1-17-11-29-32(13-17)14-18-2-4-19(5-3-18)15-33-16-23(30-31-33)25(34)28-12-20-6-7-22-21(10-20)8-9-27-24(22)26/h2-11,13,16H,12,14-15H2,1H3,(H2,26,27)(H,28,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	2.80	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263252 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-3-pheny...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)-c3ccccc3)cc2)c1 Show InChI InChI=1S/C32H29N7O/c1-22-16-36-38(18-22)19-23-7-9-24(10-8-23)20-39-21-29(30(37-39)26-5-3-2-4-6-26)32(40)35-17-25-11-12-28-27(15-25)13-14-34-31(28)33/h2-16,18,21H,17,19-20H2,1H3,(H2,33,34)(H,35,40)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.68	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263213 (1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-benzyl]-3-trifl...) Show SMILES Cc1nc2[nH]ccc2c(C)c1CNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1C(F)(F)F Show InChI InChI=1S/C28H25F3N6O2/c1-17-21-10-11-32-26(21)34-18(2)22(17)13-33-27(39)23-16-37(35-25(23)28(29,30)31)15-20-8-6-19(7-9-20)14-36-12-4-3-5-24(36)38/h3-12,16H,13-15H2,1-2H3,(H,32,34)(H,33,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.72	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263263 (2,5-dimethyl-1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-be...) Show SMILES Cc1cc(C(=O)NCc2ccc3c(N)nccc3c2)c(C)n1Cc1ccc(Cn2ccccc2=O)cc1 Show InChI InChI=1S/C30H29N5O2/c1-20-15-27(30(37)33-17-24-10-11-26-25(16-24)12-13-32-29(26)31)21(2)35(20)19-23-8-6-22(7-9-23)18-34-14-4-3-5-28(34)36/h3-16H,17-19H2,1-2H3,(H2,31,32)(H,33,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	3.90	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263317 (3-amino-1-(6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-1...) Show SMILES Nc1nn(Cc2ccc(nc2)N2CCCC2)cc1C(=O)NCc1ccc2c(N)nccc2c1 Show InChI InChI=1S/C24H26N8O/c25-22-19-5-3-16(11-18(19)7-8-27-22)12-29-24(33)20-15-32(30-23(20)26)14-17-4-6-21(28-13-17)31-9-1-2-10-31/h3-8,11,13,15H,1-2,9-10,12,14H2,(H2,25,27)(H2,26,30)(H,29,33)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4.15	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263228 (3-cyclobutyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-be...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C3CCC3)cc2)c1 Show InChI InChI=1S/C30H31N7O/c1-20-14-34-36(16-20)17-21-5-7-22(8-6-21)18-37-19-27(28(35-37)24-3-2-4-24)30(38)33-15-23-9-10-26-25(13-23)11-12-32-29(26)31/h5-14,16,19,24H,2-4,15,17-18H2,1H3,(H2,31,32)(H,33,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4.62	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263262 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-3-thiop...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)-c3ccsc3)cc2)c1 Show InChI InChI=1S/C30H27N7OS/c1-20-13-34-36(15-20)16-21-2-4-22(5-3-21)17-37-18-27(28(35-37)25-9-11-39-19-25)30(38)33-14-23-6-7-26-24(12-23)8-10-32-29(26)31/h2-13,15,18-19H,14,16-17H2,1H3,(H2,31,32)(H,33,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4.85	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM261344 (1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-benzyl]-3-trifl...) Show SMILES FC(F)(F)c1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cnc2[nH]ccc2c1 Show InChI InChI=1S/C26H21F3N6O2/c27-26(28,29)23-21(25(37)32-13-19-11-20-8-9-30-24(20)31-12-19)16-35(33-23)15-18-6-4-17(5-7-18)14-34-10-2-1-3-22(34)36/h1-12,16H,13-15H2,(H,30,31)(H,32,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.38	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263281 (1-[6-((s)-3-methyl-pyrrolidin-1-yl)-pyridin-3-ylme...) Show SMILES C[C@H]1CCN(C1)c1ccc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(n2)C(F)(F)F)cn1 Show InChI InChI=1S/C26H26F3N7O/c1-16-7-9-35(13-16)22-5-3-18(12-32-22)14-36-15-21(23(34-36)26(27,28)29)25(37)33-11-17-2-4-20-19(10-17)6-8-31-24(20)30/h2-6,8,10,12,15-16H,7,9,11,13-14H2,1H3,(H2,30,31)(H,33,37)/t16-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.84	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263236 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-3-morph...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)N3CCOCC3)cc2)c1 Show InChI InChI=1S/C30H32N8O2/c1-21-15-34-37(17-21)18-22-2-4-23(5-3-22)19-38-20-27(29(35-38)36-10-12-40-13-11-36)30(39)33-16-24-6-7-26-25(14-24)8-9-32-28(26)31/h2-9,14-15,17,20H,10-13,16,18-19H2,1H3,(H2,31,32)(H,33,39)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6.46	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263240 (3-cyclopropyl-1-(5-methoxy-6-pyrrolidin-1-yl-pyrid...) Show SMILES COc1cc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(n2)C2CC2)cnc1N1CCCC1 Show InChI InChI=1S/C28H31N7O2/c1-37-24-13-19(15-31-27(24)34-10-2-3-11-34)16-35-17-23(25(33-35)20-5-6-20)28(36)32-14-18-4-7-22-21(12-18)8-9-30-26(22)29/h4,7-9,12-13,15,17,20H,2-3,5-6,10-11,14,16H2,1H3,(H2,29,30)(H,32,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	7.31	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263282 (1-[6-((s)-3-fluoro-pyrrolidin-1-yl)-pyridin-3-ylme...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(nc4)N4CC[C@H](F)C4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C25H23F4N7O/c26-18-6-8-35(13-18)21-4-2-16(11-32-21)12-36-14-20(22(34-36)25(27,28)29)24(37)33-10-15-1-3-19-17(9-15)5-7-31-23(19)30/h1-5,7,9,11,14,18H,6,8,10,12-13H2,(H2,30,31)(H,33,37)/t18-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9.61	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263239 (1-(6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-3-trifluo...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(nc4)N4CCCC4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C25H24F3N7O/c26-25(27,28)22-20(24(36)32-12-16-3-5-19-18(11-16)7-8-30-23(19)29)15-35(33-22)14-17-4-6-21(31-13-17)34-9-1-2-10-34/h3-8,11,13,15H,1-2,9-10,12,14H2,(H2,29,30)(H,32,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9.66	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263286 (1-(2-pyrrolidin-1-yl-pyrimidin-5-ylmethyl)-3-trifl...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4cnc(nc4)N4CCCC4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C24H23F3N8O/c25-24(26,27)20-19(22(36)30-10-15-3-4-18-17(9-15)5-6-29-21(18)28)14-35(33-20)13-16-11-31-23(32-12-16)34-7-1-2-8-34/h3-6,9,11-12,14H,1-2,7-8,10,13H2,(H2,28,29)(H,30,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	10.4	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263309 (3-cyclopropyl-1-(6-pyrrolidin-1-yl-pyridin-3-ylmet...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(nc4)N4CCCC4)nc3C3CC3)ccc12 Show InChI InChI=1S/C27H29N7O/c28-26-22-7-3-18(13-21(22)9-10-29-26)14-31-27(35)23-17-34(32-25(23)20-5-6-20)16-19-4-8-24(30-15-19)33-11-1-2-12-33/h3-4,7-10,13,15,17,20H,1-2,5-6,11-12,14,16H2,(H2,28,29)(H,31,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11.6	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263285 (1-[6-((r)-2-methyl-pyrrolidin-1-yl)-pyridin-3-ylme...) Show SMILES C[C@@H]1CCCN1c1ccc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(n2)C(F)(F)F)cn1 Show InChI InChI=1S/C26H26F3N7O/c1-16-3-2-10-36(16)22-7-5-18(13-32-22)14-35-15-21(23(34-35)26(27,28)29)25(37)33-12-17-4-6-20-19(11-17)8-9-31-24(20)30/h4-9,11,13,15-16H,2-3,10,12,14H2,1H3,(H2,30,31)(H,33,37)/t16-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12.3	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263326 (3-amino-1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-benzyl]...) Show SMILES Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc2[nH]ncc12 Show InChI InChI=1S/C25H23N7O2/c26-24-21(25(34)27-12-19-4-3-5-22-20(19)13-28-29-22)16-32(30-24)15-18-9-7-17(8-10-18)14-31-11-2-1-6-23(31)33/h1-11,13,16H,12,14-15H2,(H2,26,30)(H,27,34)(H,28,29)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13.3	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263280 (1-[6-((r)-3-methyl-pyrrolidin-1-yl)-pyridin-3-ylme...) Show SMILES C[C@@H]1CCN(C1)c1ccc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(n2)C(F)(F)F)cn1 Show InChI InChI=1S/C26H26F3N7O/c1-16-7-9-35(13-16)22-5-3-18(12-32-22)14-36-15-21(23(34-36)26(27,28)29)25(37)33-11-17-2-4-20-19(10-17)6-8-31-24(20)30/h2-6,8,10,12,15-16H,7,9,11,13-14H2,1H3,(H2,30,31)(H,33,37)/t16-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13.3	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263284 (1-[6-((s)-2-methyl-pyrrolidin-1-yl)-pyridin-3-ylme...) Show SMILES C[C@H]1CCCN1c1ccc(Cn2cc(C(=O)NCc3ccc4c(N)nccc4c3)c(n2)C(F)(F)F)cn1 Show InChI InChI=1S/C26H26F3N7O/c1-16-3-2-10-36(16)22-7-5-18(13-32-22)14-35-15-21(23(34-35)26(27,28)29)25(37)33-12-17-4-6-20-19(11-17)8-9-31-24(20)30/h4-9,11,13,15-16H,2-3,10,12,14H2,1H3,(H2,30,31)(H,33,37)/t16-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13.6	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263310 (3-cyclopropyl-1-(4-[1,2,3]triazol-1-ylmethyl-benzy...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(Cn5ccnn5)cc4)nc3C3CC3)ccc12 Show InChI InChI=1S/C27H26N8O/c28-26-23-8-5-20(13-22(23)9-10-29-26)14-30-27(36)24-17-35(32-25(24)21-6-7-21)16-19-3-1-18(2-4-19)15-34-12-11-31-33-34/h1-5,8-13,17,21H,6-7,14-16H2,(H2,28,29)(H,30,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13.8	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263331 (1-[4-(4-methyl-pyrazol-1-ylmethyl)-benzyl]-1h-pyra...) Show SMILES Cc1cnn(Cc2ccc(Cn3cc(cn3)C(=O)NCc3c(C)nc4[nH]ccc4c3C)cc2)c1 Show InChI InChI=1S/C26H27N7O/c1-17-10-29-32(13-17)14-20-4-6-21(7-5-20)15-33-16-22(11-30-33)26(34)28-12-24-18(2)23-8-9-27-25(23)31-19(24)3/h4-11,13,16H,12,14-15H2,1-3H3,(H,27,31)(H,28,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263214 (2,5-dimethyl-1-[4-(4-methyl-pyrazol-1-ylmethyl)-be...) Show SMILES Cc1cnn(Cc2ccc(Cn3c(C)cc(C(=O)NCc4ccc5c(N)nccc5c4)c3C)cc2)c1 Show InChI InChI=1S/C29H30N6O/c1-19-14-33-34(16-19)17-22-4-6-23(7-5-22)18-35-20(2)12-27(21(35)3)29(36)32-15-24-8-9-26-25(13-24)10-11-31-28(26)30/h4-14,16H,15,17-18H2,1-3H3,(H2,30,31)(H,32,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14.3	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263287 (1-(5-pyrrolidin-1-yl-pyrazin-2-ylmethyl)-3-trifluo...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4cnc(cn4)N4CCCC4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C24H23F3N8O/c25-24(26,27)21-19(23(36)32-10-15-3-4-18-16(9-15)5-6-29-22(18)28)14-35(33-21)13-17-11-31-20(12-30-17)34-7-1-2-8-34/h3-6,9,11-12,14H,1-2,7-8,10,13H2,(H2,28,29)(H,32,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14.9	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263279 (1-[6-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-3-ylme...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(nc4)N4CCC(F)(F)C4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C25H22F5N7O/c26-24(27)6-8-36(14-24)20-4-2-16(11-33-20)12-37-13-19(21(35-37)25(28,29)30)23(38)34-10-15-1-3-18-17(9-15)5-7-32-22(18)31/h1-5,7,9,11,13H,6,8,10,12,14H2,(H2,31,32)(H,34,38)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14.9	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263275 (5-amino-1-(4-pyrazol-1-ylmethyl-benzyl)-1h-pyrazol...) Show SMILES Nc1c(cnn1Cc1ccc(Cn2cccn2)cc1)C(=O)NCc1ccc2c(N)nccc2c1 Show InChI InChI=1S/C25H24N8O/c26-23-21-7-6-19(12-20(21)8-10-28-23)13-29-25(34)22-14-31-33(24(22)27)16-18-4-2-17(3-5-18)15-32-11-1-9-30-32/h1-12,14H,13,15-16,27H2,(H2,26,28)(H,29,34)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	16.8	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263308 (3-cyclopropyl-1-(4-methoxy-6-pyrrolidin-1-yl-pyrid...) Show SMILES COc1cc(ncc1Cn1cc(C(=O)NCc2ccc3c(N)nccc3c2)c(n1)C1CC1)N1CCCC1 Show InChI InChI=1S/C28H31N7O2/c1-37-24-13-25(34-10-2-3-11-34)31-15-21(24)16-35-17-23(26(33-35)19-5-6-19)28(36)32-14-18-4-7-22-20(12-18)8-9-30-27(22)29/h4,7-9,12-13,15,17,19H,2-3,5-6,10-11,14,16H2,1H3,(H2,29,30)(H,32,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	17.8	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263283 (1-[6-((r)-3-fluoro-pyrrolidin-1-yl)-pyridin-3-ylme...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(nc4)N4CC[C@@H](F)C4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C25H23F4N7O/c26-18-6-8-35(13-18)21-4-2-16(11-32-21)12-36-14-20(22(34-36)25(27,28)29)24(37)33-10-15-1-3-19-17(9-15)5-7-31-23(19)30/h1-5,7,9,11,14,18H,6,8,10,12-13H2,(H2,30,31)(H,33,37)/t18-/m1/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	18.1	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263315 (1-(5-chloro-6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4cnc(N5CCCC5)c(Cl)c4)nc3C3CC3)ccc12 Show InChI InChI=1S/C27H28ClN7O/c28-23-12-18(14-31-26(23)34-9-1-2-10-34)15-35-16-22(24(33-35)19-4-5-19)27(36)32-13-17-3-6-21-20(11-17)7-8-30-25(21)29/h3,6-8,11-12,14,16,19H,1-2,4-5,9-10,13,15H2,(H2,29,30)(H,32,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	18.5	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263304 (1-[2-(4-methyl-pyrazol-1-ylmethyl)-thiazol-4-ylmet...) Show SMILES Cc1cnn(Cc2nc(Cn3cc(C(=O)NCc4ccc5c(N)nccc5c4)c(n3)C(F)(F)F)cs2)c1 Show InChI InChI=1S/C24H21F3N8OS/c1-14-7-31-34(9-14)12-20-32-17(13-37-20)10-35-11-19(21(33-35)24(25,26)27)23(36)30-8-15-2-3-18-16(6-15)4-5-29-22(18)28/h2-7,9,11,13H,8,10,12H2,1H3,(H2,28,29)(H,30,36)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	21.2	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263295 (1-(5-fluoro-6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4cnc(N5CCCC5)c(F)c4)nc3C(F)(F)F)ccc12 Show InChI InChI=1S/C25H23F4N7O/c26-20-10-16(12-32-23(20)35-7-1-2-8-35)13-36-14-19(21(34-36)25(27,28)29)24(37)33-11-15-3-4-18-17(9-15)5-6-31-22(18)30/h3-6,9-10,12,14H,1-2,7-8,11,13H2,(H2,30,31)(H,33,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	22.6	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263339 (1-[4-(2-oxo-2h-pyridin-1-ylmethyl)-benzyl]-3-trifl...) Show SMILES FC(F)(F)c1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc2[nH]ncc12 Show InChI InChI=1S/C26H21F3N6O2/c27-26(28,29)24-21(25(37)30-12-19-4-3-5-22-20(19)13-31-32-22)16-35(33-24)15-18-9-7-17(8-10-18)14-34-11-2-1-6-23(34)36/h1-11,13,16H,12,14-15H2,(H,30,37)(H,31,32)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	22.9	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263306 (3-cyclopropyl-1-[6-(3,3-difluoro-pyrrolidin-1-yl)-...) Show SMILES Nc1nccc2cc(CNC(=O)c3cn(Cc4ccc(nc4)N4CCC(F)(F)C4)nc3C3CC3)ccc12 Show InChI InChI=1S/C27H27F2N7O/c28-27(29)8-10-35(16-27)23-6-2-18(13-32-23)14-36-15-22(24(34-36)19-3-4-19)26(37)33-12-17-1-5-21-20(11-17)7-9-31-25(21)30/h1-2,5-7,9,11,13,15,19H,3-4,8,10,12,14,16H2,(H2,30,31)(H,33,37)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	23.2	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair
Plasma kallikrein (Homo sapiens (Human))	BDBM263341 (1-(6-pyrrolidin-1-yl-pyridin-3-ylmethyl)-3-trifluo...) Show SMILES FC(F)(F)c1nn(Cc2ccc(nc2)N2CCCC2)cc1C(=O)ONC(=O)c1n[nH]c2ccc(Cl)cc12 Show InChI InChI=1S/C23H19ClF3N7O3/c24-14-4-5-17-15(9-14)19(30-29-17)21(35)32-37-22(36)16-12-34(31-20(16)23(25,26)27)11-13-3-6-18(28-10-13)33-7-1-2-8-33/h3-6,9-10,12H,1-2,7-8,11H2,(H,29,30)(H,32,35)	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	24.9	n/a	n/a	n/a	n/a	n/a	n/a
Kalvista Pharmaceuticals Limited US Patent					Assay Description Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...				US Patent US9533987 (2017) BindingDB Entry DOI: 10.7270/Q2SX6G78
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 286 total )  |  Next  |  Last  >>

Jump to: